METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application Ser. No. 62/855,454 filed on May 31, 2019, which is incorporated by reference herein in its entirety.

SUMMARY ~~OF THE INVENTION~~

[0001a] In one aspect, provided herein is the use of nanatinostat in the manufacture of a first medicament and use of an effective amount of an antiviral agent in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat an Epstein-Barr virus associated lymphoproliferative disorder in an individual, wherein the nanatinostat is to be administered at a total daily dose from 10 milligrams to 20 milligrams per day, wherein the individual is to be treated according to a treatment schedule having a duration of one week, and wherein the individual is to be administered nanatinostat for 4 days of the treatment schedule.

[0001b] In another aspect, provided herein is the use of nanatinostat in the manufacture of a first medicament and use of valganciclovir in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat an Epstein-Barr virus associated lymphoproliferative disorder in an individual, wherein the nanatinostat is to be administered at a total daily dose of about 20 mg, wherein the valganciclovir is to be administered at a total daily dose of about 900 mg, wherein the individual is to be treated according to a weekly treatment schedule, and wherein the individual is to be administered nanatinostat for 4 consecutive days of the treatment schedule, and valganciclovir is to be administered every day of the treatment schedule.

[0002] Described herein are certain dosing schedules and amounts that effectively provide efficacy and prevent and manage side effects associated with treatment of histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.

[0003] Described herein, in one ~~aspect~~example, is a method of treating a cancer in an individual, the method comprising administering to the individual: (a) an effective amount of a histone deacetylase inhibitor (HDACi) as a viral inducing agent, wherein the HDACi is characterized by an elimination half-life of less than 30 hours; and (b) an effective amount of an antiviral drug; wherein the individual is treated according to a treatment schedule, wherein the individual is administered a lower dosage of the HDACi for at least one dose of the treatment schedule. In

certain ~~embodiment~~examples, the individual is not administered the HDACi for at least one day of the treatment schedule. In certain ~~embodiment~~examples, the HDACi is administered orally. In certain ~~embodiment~~examples, the HDACi is selected from the list consisting of: vorinostat, romidepsin, mocetinostat, belinostat, pracinostat, givinostat, panobinostat, CUDC-101, CDX101, chidamide, domatinostat, and nanatinostat. In certain ~~embodiment~~examples, the HDACi inhibits activity of a class I histone deacetylase. In certain ~~embodiment~~examples, the HDACi is characterized by an elimination half-life of less than 24 hours. In certain ~~embodiment~~examples, the HDACi is characterized by an elimination half-life of less than 12 hours. In certain ~~embodiment~~examples, the HDACi is characterized by an elimination half-life of less than 4 hours. In certain ~~embodiment~~examples, the HDACi is nanatinostat. In certain ~~embodiment~~examples, the HDACi is administered at a total daily dose from about 10 milligrams to about 40 milligrams. In certain ~~embodiment~~examples, the HDACi is administered at a total daily dose of about 10 milligrams. In certain ~~embodiment~~examples, the HDACi is administered at a total daily dose of about 15 milligrams. In certain ~~embodiment~~examples, the HDACi is administered at a total daily dose of about 20 milligrams. In certain ~~embodiment~~examples, the HDACi is administered at a total daily dose of about 25 milligrams. In certain ~~embodiment~~examples, the HDACi is administered at a total daily dose of

about 30 milligrams. In certain ~~embodiment~~examples, the HDACi is administered once per day. In certain ~~embodiment~~examples, the HDACi is administered twice per day. In certain ~~embodiment~~examples, the cytotoxic activity of the antiviral agent is activated by a viral kinase. In certain ~~embodiment~~examples, the viral kinase comprises, an Epstein-Barr virus protein kinase, an Epstein-Barr virus thymidine kinase, a human herpes virus thymidine kinase, or a human cytomegalovirus protein. In certain ~~embodiment~~examples, the antiviral agent is selected from the list consisting of aciclovir, ganciclovir, valaciclovir, valganciclovir, and famciclovir. In certain ~~embodiment~~examples, the antiviral agent is valganciclovir. In certain ~~embodiment~~examples, the antiviral agent is administered at a total daily dose of 1800 milligrams. In certain ~~embodiment~~examples, the antiviral agent is administered at a total daily dose of 900 milligrams. In certain ~~embodiment~~examples, the antiviral agent is administered at a total daily dose of 450 milligrams. In certain ~~embodiment~~examples, the antiviral agent is administered every day of the treatment schedule. In certain ~~embodiment~~examples, the antiviral agent is administered orally. In certain ~~embodiment~~examples, the individual is not administered the HDACi for at least two days of the treatment schedule. In certain ~~embodiment~~examples, the individual is not administered the HDACi for at least three days of the treatment schedule. In certain ~~embodiment~~examples, the individual is not administered the HDACi for at least four days of the treatment schedule. In certain ~~embodiment~~examples, the individual is not administered the HDACi for at least five days of the treatment schedule. In certain ~~embodiment~~examples, the treatment schedule has a duration of one week. In certain ~~embodiment~~examples, the treatment schedule is repeated. In certain ~~embodiment~~examples, the HDACi is administered with food or a caloric substance. In certain ~~embodiment~~examples, the cancer is a solid tissue cancer. In certain ~~embodiment~~examples, the solid tissue cancer is salivary gland cancer, nasopharyngeal carcinoma, head and neck cancer, gastric cancer, a colorectal cancer, breast cancer, glioblastoma, prostate cancer, renal cancer, leiomyosarcoma, pancreatic cancer, or lung cancer. In certain ~~embodiment~~examples, the solid tissue cancer is salivary gland cancer, nasopharyngeal carcinoma, head and neck cancer, gastric cancer, a colorectal cancer, or leiomyosarcoma. In certain ~~embodiment~~examples, the cancer is a leukemia or a lymphoma. In certain ~~embodiment~~examples, the leukemia or lymphoma is a B cell leukemia or lymphoma. In certain ~~embodiment~~examples, the leukemia or lymphoma is a T cell leukemia or lymphoma. In certain ~~embodiment~~examples, the leukemia or lymphoma is non-Hodgkin’s lymphoma. In certain ~~embodiment~~examples, the leukemia or lymphoma is Hodgkin’s lymphoma. In certain ~~embodiment~~examples, the leukemia or lymphoma is a cytomegalovirus virus positive leukemia or lymphoma. In certain ~~embodiment~~examples, the leukemia or lymphoma is an Epstein-Barr virus positive leukemia or lymphoma. In certain ~~embodiment~~examples, the individual is afflicted with thrombocytopenia. In

certain ~~embodiment~~examples, the individual has a platelet count of less than 50,000 platelets per microliter. In certain ~~embodiment~~examples, the individual has an elevated creatinine level. In certain ~~embodiment~~examples, the elevated creatinine level exceeds 1.1 mg/dL for a woman or 1.3 mg/dL for a man. In certain ~~embodiment~~examples, the individual is selected for treatment according to the treatment schedule based on the presence of thrombocytopenia. In certain ~~embodiment~~examples, the individual is selected based on a platelet count of less than 50,000 per microliter. In certain ~~embodiment~~examples, the individual is selected for treatment according to the treatment schedule based on the presence of an elevated creatinine level. In certain ~~embodiment~~examples, the elevated creatinine level exceeds 1.1 mg/dL for a woman and 1.3 mg/dL for a man.

[0004] In another ~~aspect~~example, described herein, is a method of treating an Epstein-Barr associated lymphoma in an individual, the method comprising administering to the individual: (a) an effective amount of nanatinostat; and (b) an effective amount of valganciclovir; wherein the individual is treated according to a treatment schedule, wherein the individual is not administered the nanatinostat for at least three days of the treatment schedule.

[0005] In another ~~aspect~~example, described herein, is a kit comprising: (a) an HDACi as a viral inducing agent; and (b) an antiviral agent as a cytotoxic anti-cancer agent; wherein the kit comprises a plurality of oral dosage forms, the oral dosage forms comprising the HDACi and the antiviral agent co-packaged into separate oral dosage forms. In another ~~aspect~~example, described herein, is a kit comprising: (a) an HDACi; and (b) an antiviral agent; wherein the kit comprises a plurality of oral dosage forms, the oral dosage forms comprising the HDACi and the antiviral agent co-formulated into a single oral dosage form, wherein at least one of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi. In certain ~~embodiment~~examples, the plurality of oral dosage forms are a pill, capsule, tablet, or gel cap. In certain ~~embodiment~~examples, the HDACi is selected from the list consisting of: vorinostat, romidepsin, mocetinostat, belinostat, pracinostat, givinostat, panobinostat, CUDC-101, CDX101, chidamide, and nanatinostat. In certain ~~embodiment~~examples, the HDACi inhibits activity of a class I histone deacetylase. In certain ~~embodiment~~examples, the HDACi is characterized by an elimination half-life of less than 24 hours. In certain ~~embodiment~~examples, the HDACi is characterized by an elimination half-life of less than 12 hours. In certain ~~embodiment~~examples, the HDACi is characterized by an elimination half-life of less than 4 hours. In certain ~~embodiment~~examples, the HDACi is nanatinostat. In certain ~~embodiment~~examples, the cytotoxic activity of the antiviral agent is activated by a viral kinase. In certain ~~embodiment~~examples, the viral kinase comprises, an Epstein-Barr virus protein kinase, an Epstein-Barr virus thymidine kinase, a human herpes virus thymidine kinase, or a human cytomegalovirus protein. In certain

~~embodiment~~examples, the antiviral agent is selected from the list consisting of aciclovir, ganciclovir, valaciclovir, valganciclovir, and famciclovir. In certain ~~embodiment~~examples, the antiviral agent is valganciclovir. In certain ~~embodiment~~examples, the plurality of oral dosage forms comprise about 900mg of valganciclovir. In certain ~~embodiment~~examples, the plurality of oral dosage forms comprise about 450mg of valganciclovir. In certain ~~embodiment~~examples, the plurality of oral dosage forms comprise about 20mg of nanatinostat. In certain ~~embodiment~~examples, the plurality of oral dosage forms comprise about 15mg of nanatinostat. In certain ~~embodiment~~examples, the plurality of oral dosage forms comprise about 10mg of nanatinostat. In certain ~~embodiment~~examples, the plurality of oral dosage forms comprise seven or a multiple thereof. In certain ~~embodiment~~examples, one of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi. In certain ~~embodiment~~examples, two of the plurality of oral dosage forms comprises the antiviral agent and a lower dosage amount of the HDACi. In certain ~~embodiment~~examples, two of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi. In certain ~~embodiment~~examples, three of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi. In certain ~~embodiment~~examples, four of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi. In certain ~~embodiment~~examples, five of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi. In certain ~~embodiment~~examples, the HDACi comprises nanatinostat and the antiviral agent comprise valganciclovir.

INCORPORATION BY REFERENCE

[0006] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0008] FIG. 1 illustrates rapid recovery of platelet counts in patients on nanatinostat dose hold.

CLAIMS

What is claimed is:

1. Use of nanatinostat in the manufacture of a first medicament and use of an effective amount of an antiviral agent in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat an Epstein-Barr virus associated lymphoproliferative disorder in an individual

   wherein the nanatinostat is to be ~~A method of treating a cancer in an individual, the method comprising administering~~ administered at a total daily dose from 10 milligrams to 20 milligrams per day,~~to the individual: (a) an effective amount of a histone deacetylase inhibitor (HDACi), wherein the HDACi is characterized by an elimination half-life of less than 30 hours; and (b) an effective amount of an antiviral drug;~~

   wherein the individual is to be treated according to a treatment schedule having a duration of one week, and

   wherein the individual is to be ~~not~~ administered nanatinostat~~the HDACi~~ for 4 days~~at least one dose~~ of the treatment schedule.

~~2. The method of claim 1, wherein the individual is not administered the HDACi for at least one day of the treatment schedule~~

~~3. The method of claim 1 or 2, wherein the HDACi is administered orally.~~

~~4. The method of any one of claims 1 to 3, wherein the HDACi is selected from the list consisting of: vorinostat, romidepsin, mocetinostat, belinostat, pracinostat, givinostat, panobinostat, CUDC-101, CDX101, chidamide, domatinostat, and nanatinostat.~~

~~5. The method of any one of claims 1 to 4, wherein the HDACi inhibits activity of a class I histone deacetylase.~~

~~6. The method of any one of claims 1 to 5, wherein the HDACi is characterized by an elimination half-life of less than 24 hours.~~

~~7. The method of any one of claims 1 to 5, wherein the HDACi is characterized by an elimination half-life of less than 12 hours.~~

~~8. The method of any one of claims 1 to 5, wherein the HDACi is characterized by an elimination half-life of less than 4 hours.~~

~~9. The method of any one of claims 1 to 8, wherein the HDACi is nanatinostat.~~

~~10. The method of any one of claims 1 to 9, wherein the HDACi is administered at a total daily dose from about 10 milligrams to about 40 milligrams.~~

~~11.~~2. The use~~method~~ of claim 1~~0~~, wherein the nanatinostat~~HDACi~~ is to be administered at a total daily dose of ~~about~~ 10 milligrams.

~~12. The method of claim 10, wherein the HDACi is administered at a total daily dose of about 15 milligrams.~~

~~13.~~3. The use~~method~~ of claim 1~~0~~, wherein the nanatinostat~~HDACi~~ is to be administered at a total daily dose of ~~about~~ 20 milligrams.

~~14. The method of claim 10, wherein the HDACi is administered at a total daily dose of about 25 milligrams.~~

~~15. The method of claim 10, wherein the HDACi is administered at a total daily dose of about 30 milligrams.~~

~~16.~~4. The use~~method~~ of ~~any one of~~ claim~~s~~ 1~~0 to 15~~, wherein the nanatinostat~~HDACi~~ is to be administered once per day.

5. The use of claim 1, wherein the nanatinostat is to be administered twice per day.

~~17. The method of any one of claims 1 to 16, wherein the cytotoxic activity of the antiviral agent is activated by a viral kinase.~~

~~18. The method of claim 17, wherein the viral kinase comprises, an Epstein-Barr virus protein kinase, an Epstein-Barr virus thymidine kinase, a human herpes virus thymidine kinase, or a human cytomegalovirus protein.~~

~~19.~~6. The use~~method~~ of ~~any one of~~ claim~~s~~ 1 ~~to 18~~, wherein the antiviral agent is ~~selected from the list consisting of aciclovir, ganciclovir, valaciclovir,~~ valganciclovir~~, and famciclovir~~.

~~20. The method of claim 19, wherein the antiviral agent is valganciclovir.~~

~~21.~~7. The use~~method~~ of ~~any one of~~ claim~~s~~ ~~6~~1 ~~to 20~~, wherein the valganciclovir~~antiviral agent~~ is to be administered at a total daily dose of 1,800 milligrams.

~~22.~~8. The use~~method~~ of ~~any one of~~ claim~~s~~ ~~6~~1 ~~to 20~~, wherein the valganciclovir~~antiviral agent~~ is to be administered at a total daily dose of 900 milligrams.

~~23.~~9. The use~~method~~ of ~~any one of~~ claim~~s~~ ~~6~~1 ~~to 20~~, wherein the valganciclovir~~antiviral agent~~ is to be administered at a total daily dose of 450 milligrams.

~~24.~~10. The use~~method~~ of ~~any one of~~ claim~~s~~ 1 ~~to 23~~, wherein the antiviral agent is to be administered every day of the treatment schedule.

~~25.~~11. The use~~method~~ of ~~any one of~~ claim~~s~~ 1 ~~to 23~~, wherein the antiviral agent is not to be administered on one or more days of the treatment schedule.

12. The use of claim 1, wherein the antiviral agent is to be administered once a day.

13. The use of claim 1, wherein the antiviral agent is to be administered twice a day.

~~26.~~14. The use~~method~~ of ~~any one of~~ claim~~s~~ 1 ~~to 25~~, wherein the antiviral agent is to be administered orally.

15. The use of claim 1, wherein the nanatinostat is to be administered orally.

~~27. The method of any one of claims 1 to 26, wherein the individual is not administered the HDACi for at least two days of the treatment schedule.~~

~~28. The method of any one of claims 1 to 26, wherein the individual is not administered the HDACi for at least three days of the treatment schedule.~~

~~29. The method of any one of claims 1 to 26, wherein the individual is not administered the HDACi for at least four days of the treatment schedule.~~

~~30. The method of any one of claims 1 to 26, wherein the individual is not administered the HDACi for at least five days of the treatment schedule.~~

~~31. The method of any one of claims 1 to 30, wherein the treatment schedule has a duration of one week.~~

~~32.~~16. The use~~method~~ of ~~any one of~~ claim~~s~~ 1 ~~to 31~~, wherein the treatment schedule is to be repeated.

17. The use of claim 1, wherein the Epstein-Barr virus associated lymphoproliferative disorder is an Epstein-Barr virus associated leukemia or a lymphoma.

~~33. The method of any one of claims 1 to 32, wherein the HDACi is administered with food or a caloric substance.~~

~~34. The method of any one of claims 1 to 33, wherein the cancer is a solid tissue cancer.~~

~~35. The method of claim 34, wherein the solid tissue cancer is salivary gland cancer, nasopharyngeal carcinoma, head and neck cancer, gastric cancer, a colorectal cancer, breast cancer, glioblastoma, prostate cancer, renal cancer, leiomyosarcoma, pancreatic cancer, or lung cancer.~~

~~36. The method of claim 34, wherein the solid tissue cancer is salivary gland cancer, nasopharyngeal carcinoma, head and neck cancer, gastric cancer, a colorectal cancer, or leiomyosarcoma.~~

~~37. The method of any one of claims 1 to 33, wherein the cancer is a leukemia or a lymphoma.~~

~~38.~~18. The use~~method~~ of claim ~~3~~17, wherein the leukemia or lymphoma is a B cell or a T cell leukemia or lymphoma.

~~39. The method of claim 37, wherein the leukemia or lymphoma is a T cell leukemia or lymphoma.~~

~~40. The method of claim 37, wherein the leukemia or lymphoma is non-Hodgkin's lymphoma.~~

~~41. The method of claim 37, wherein the leukemia or lymphoma is Hodgkin's lymphoma.~~

~~42. The method of claim 37, wherein the leukemia or lymphoma is a cytomegalovirus virus positive leukemia or lymphoma.~~

~~43. The method of claim 37, wherein the leukemia or lymphoma is an Epstein-Barr virus positive leukemia or lymphoma.~~

~~44.~~19. The use~~method~~ of ~~any one of~~ claim~~s~~ 1 ~~to 43~~, wherein the individual is afflicted with thrombocytopenia.

~~45.~~20. The use~~method~~ of claim 1~~44~~, wherein the individual has a platelet count of less than 150,000 platelets per microliter.

~~46. The method of claim 44, wherein the individual has a platelet count of less than 50,000 platelets per microliter.~~

~~47. The method of any one of claims 1 to 43, wherein the individual has an elevated creatinine level.~~

~~48. The method of claim 47, wherein the elevated creatinine level exceeds 1.1 mg/dL for a woman or 1.3 mg/dL for a man.~~

~~49. The method of any one of claims 1 to 48, wherein the individual is selected for treatment according to the treatment schedule based on the presence of thrombocytopenia.~~

~~50. The method of claim 48, wherein the individual is selected based on a platelet count of less than 50,000 per microliter.~~

~~51. The method of any one of claims 1 to 48, wherein the individual is selected for treatment according to the treatment schedule based on the presence of an elevated creatinine level.~~

~~52. The method of claim 51, wherein the elevated creatinine level exceeds 1.1 mg/dL for a woman and 1.3 mg/dL for a man.~~

~~53.~~21. Use of nanatinostat in the manufacture of a first medicament and use of valganciclovir in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy~~A method of~~ to treat~~ing~~ an Epstein-Barr virus ~~-~~associated lymphoproliferative disorder~~lymphoma~~ in an individual,

wherein the nanatinostat is to be~~the method comprising~~ administered at a total daily dose of about 20mg~~ing to the individual: (a) an effective amount of nanatinostat; and~~,

wherein the~~(b) an effective amount of~~ valganciclovir is to be administered at a total daily dose of about 900 mg.~~;~~

wherein the individual is to be treated according to a weekly treatment schedule, and wherein

the individual is to be ~~not~~ administered ~~the~~ nanatinostat for 4~~at least three~~ consecutive days of the treatment schedule~~,~~ and valganciclovir is to be administered every day of the treatment schedule.

22. The use of claim 21, wherein nanatinostat and valganciclovir are to be administered orally.

23. The use of claim 21, wherein nanatinostat and valganciclovir are each to be administered once a day.

24. The use of claim 21, wherein nanatinostat and valganciclovir are each to be administered twice a day.

25. The use of claim 21, wherein the treatment schedule is to be repeated.

~~54. The method of claim 53, wherein the individual is not administered the nanatinostat for at least four days of the treatment schedule.~~

~~55. The method of claim 53, wherein the individual is not administered the nanatinostat for at least five days of the treatment schedule.~~

~~56. A kit comprising:~~

~~a) an HDACi; and~~

~~b) an antiviral agent;~~

~~wherein the kit comprises a plurality of oral dosage forms, wherein the oral dosage forms comprising the HDACi and the antiviral agent are co-packaged or co-formulated into a single oral dosage form, wherein at least one of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi.~~

~~57. The kit of claim 56, wherein the kit comprises a plurality of oral dosage forms, wherein the oral dosage forms comprising the HDACi and the antiviral agent are co-packaged.~~

~~58. The kit of claim 56, wherein the kit comprises a plurality of oral dosage forms, wherein the oral dosage forms comprising the HDACi and the antiviral agent are co-formulated.~~

~~59. The kit of any one of claims 56 to 58, wherein the plurality of oral dosage forms are a pill, capsule, tablet, or gel cap.~~

~~60. The kit of any one of claims 56 to 59, wherein the HDACi is selected from the list consisting of: vorinostat, romidepsin, mocetinostat, belinostat, pracinostat, givinostat, panobinostat, CUDC-101, chidamide, domatinostat, and nanatinostat.~~

~~61. The kit of any one of claims 56 to 60, wherein the HDACi inhibits activity of a class I histone deacetylase.~~

~~62. The kit of any one of claims 56 to 61, wherein the HDACi is characterized by an elimination half-life of less than 24 hours.~~

~~63. The kit of any one of claims 56 to 61, wherein the HDACi is characterized by an elimination half-life of less than 12 hours.~~

~~64. The kit of any one of claims 56 to 61, wherein the HDACi is characterized by an elimination half-life of less than 4 hours.~~

~~65. The kit of any one of claims 56 to 64, wherein the HDACi is nanatinostat.~~

~~66. The kit of any one of claims 56 to 65, wherein the cytotoxic activity of the antiviral agent is activated by a viral kinase.~~

~~67. The kit of claim 66, wherein the viral kinase comprises, an Epstein-Barr virus protein kinase, an Epstein-Barr virus thymidine kinase, a human herpes virus thymidine kinase, or a human cytomegalovirus protein.~~

~~68. The kit of any one of claims 56 to 67, wherein the antiviral agent is selected from the list consisting of aciclovir, ganciclovir, valaciclovir, valganciclovir, and famciclovir.~~

~~69. The kit of claim 67, wherein the antiviral agent is valganciclovir.~~

~~70. The kit of any one of claims 56 to 69, wherein the plurality of oral dosage forms comprises about 1,800 mg of valganciclovir.~~

~~71. The kit of any one of claims 56 to 69, wherein the plurality of oral dosage forms comprises about 900 mg of valganciclovir.~~

~~72. The kit of any one of claims 56 to 70, wherein the plurality of oral dosage forms comprises about 450 mg of valganciclovir.~~

~~73. The kit of any one of claims 56 to 71, wherein the plurality of oral dosage forms comprises about 20 mg of nanatinostat.~~

~~74. The kit of any one of claims 56 to 71, wherein the plurality of oral dosage forms comprises about 15 mg of nanatinostat.~~

~~75. The kit of any one of claims 56 to 71, wherein the plurality of oral dosage forms comprises about 10 mg of nanatinostat.~~

~~76. The kit of any one of claims 56 to 75, wherein the plurality comprises seven or a multiple thereof.~~

~~77. The kit of claim 76, wherein at least one of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi.~~

~~78. The kit of claim 76, wherein at least one of the plurality of oral dosage forms comprises the HDACi and does not comprise the antiviral agent.~~

~~79. The kit of claim 76, wherein two of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi.~~

~~80. The kit of claim 76, wherein three of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi.~~

~~81. The kit of claim 76, wherein four of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi.~~

~~82. The kit of claim 76, wherein five of the plurality of oral dosage forms comprises the antiviral agent and does not comprise the HDACi.~~

~~83. The kit of any one of claims 56 to 82, wherein the HDACi comprises nanatinostat and the antiviral agent comprise valganciclovir.~~